

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

BMF RABBIT PAB

货号: \$221249 产品全名: BMF 兔多抗

基因符号

UNIPROT ID: Q96LC9 (Gene Accession - NP_277038)

背景: The protein encoded by this gene belongs to the BCL2 protein family. BCL2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. This protein contains a single BCL2 homology domain 3 (BH3), and has been shown to bind BCL2 proteins and function as an apoptotic activator. This protein is found to be sequestered to myosin V motors by its association with dynein light chain 2, which may be important for sensing intracellular damage and triggering apoptosis. Alternatively spliced transcript variants encoding different isoforms have been identified.

抗原: Synthetic peptide of human BMF

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 20-100; ELISA: 2000-5000


种属反应性: Rabbit 克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Cancer


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human prostate cancer tissue using 221249 (BMF Antibody) at a dilution of 1/20 (Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with the synthetic peptide and then with 221249(Anti-BMF Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human breast cancer tissue using 221249(Anti-BMF Antibody) at a dilution of 1/20.



In comparision with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with synthetic peptide and then with D262765(Anti-BMF Antibody) at dilution 1/20.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010